Download Image
    
Share
  
Post
Verapamil for COVID-19
1 study with 144 patients
Hospital Icon Control Serious Outcome Risk
Hospital Icon Verapamil
No significant improvements are seen in meta analysis to date.
COVID-19 Verapamil studies. Dec 2025. c19early.org
0 0.5 1 1.5+ All studies 0% Mortality 0% RCTs 0% Late 0% Favorsverapamil Favorscontrol
Sep 30
2022
 Navarese et al., Cardiology Journal, doi:10.5603/CJ.a2022.0072 Ion channel inhibition with amiodarone or verapamil in symptomatic hospitalized nonintensive-care COVID-19 patients: The ReCOVery-SIRIO randomized trial
no change in mortality (p=1), 17% higher ventilation (p=1), and 3% worse recovery (p=0.8). RCT 215 hospitalized non-intensive care COVID-19 patients showing no significant difference in clinical improvement with amiodarone or verapamil. The trial, which aimed to assess the effects of ion channel inhibitors on COVID-19 progressi..